Re: "Help Me"
Penny, one of the Emilia trial inclusion criteria, a trial which became the basis for T-DM1 approval, required that patients had received:
"Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced, or metastatic setting must include both a taxane, alone or in combination with another agent, and trastuzumab, alone or in combination with another agent."
So these participants no longer- or ever did respond to trastuzumab.
T-DM1 however for many of the Emilia trial participants showed strong and lasting signals of efficacy, with reduced toxicity. I so hope this drug will also proof to be beneficial for you.
Last edited by schoonder; 06-06-2013 at 08:09 AM..
Reason: cleanup
|